Idexx Laboratories
IDEXX Laboratories, Inc. (Nasdaq: IDXX) develops, manufactures, and distributes diagnostic products and provides services for companion animal veterinary, livestock, poultry and dairy, and water testing markets; it also sells point-of-care diagnostic products for human medicine. Its Companion Animal Group provides… From the company’s description.
In fiscal 2025, Idexx Laboratories reported revenue of $4.30B, up 10.4% from fiscal 2024, and net income of $1.06B. Its operating margin was 31.6%, and operations generated $1.18B in cash. Over the twelve months to Jun 30, 2026, revenue was $4.55B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Idexx Laboratories does
In the company’s own words
IDEXX Laboratories, Inc. (Nasdaq: IDXX) develops, manufactures, and distributes diagnostic products and provides services for companion animal veterinary, livestock, poultry and dairy, and water testing markets; it also sells point-of-care diagnostic products for human medicine. Its Companion Animal Group provides veterinary analyzers, tests, reference laboratory and telemedicine services, practice-management software, and diagnostic imaging to veterinary practices and groups. Its Water segment supplies tests and instruments used by government, utility, and private laboratories to detect microbiological contaminants. The Livestock, Poultry and Dairy segment provides diagnostic tests and services to laboratories, veterinarians, producers, and processors, including tests for animal health and antibiotic residues in milk. Other includes human medical diagnostics and an out-licensing arrangement. Veterinary brands and products include Catalyst, ProCyte, SNAP, ezyVet, Cornerstone, and VetConnect PLUS; water products include Colilert and Quanti-Tray, while Alertys serves livestock pregnancy testing. The company operates a network of approximately 80 reference laboratories worldwide.
Company details
- Sector
- Health Care
- Industry (SIC)
- Chemicals
- Headquarters
- WESTBROOK, ME
- Fiscal year end
- December
- CIK
- 874716
- SIC
- 2835
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Idexx Laboratories — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Idexx Laboratories · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Idexx Laboratories’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Idexx Laboratories and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Idexx Laboratories's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Idexx Laboratories's last four quarterly filings that the numbers alone won't show?”